BRD-810

• Description :

  BRD-810 is a potent and selective MCL1 inhibitor with a Kd of 0.3 nM. BRD-810 can specifically block the BH3 binding groove of MCL1, while having little effect on other anti-apoptotic proteins (such as Bcl-2, Bcl-xL) . BRD-810 effectively destroys the MCL1-BAK complex (IC50 = 1.2 nM) in cancer cells, rapidly activates Caspase and induces cell apoptosis. BRD-810 can be used in the research of various cancers such as hematological tumors and solid tumors[1].

• UNSPSC :

  12352101

• Target :

  Apoptosis; Bcl-2 Family; Caspase

• Type :

  Reference compound

• Related Pathways :

  Apoptosis

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/brd-810.html

• Purity :

  98.00

• Solubility :

  DMSO : 100 mg/mL (ultrasonic)

• Smiles :

  O=C(O)C(N1CCCCO[C@H](CCN2CCOCC2)C3=NN(C)C(CC)=C43)=C(CCCOC5=C6C(C=C(F)C=C6)=CC=C5)C7=C1C4=C(Cl)C=C7

• Molecular Formula :

  C39H44ClFN4O5

• Molecular Weight :

  703.24

• References & Citations :

  [1]Rauh U, et al. BRD-810 is a highly selective MCL1 inhibitor with optimized in vivo clearance and robust efficacy in solid and hematological tumor models. Nat Cancer. 2024 Oct;5 (10) :1479-1493.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• Isoform :

  Caspase 3; Mcl-1

• CAS Number :

  [2329719-65-3]